



Familial Chylomicronemia Syndrome (FCS)

Familial chylomicronemia syndrome (FCS) is a rare genetic lipid disorder characterized by the build-up of chylomicrons (chylomicronemia), a large lipoprotein particle that transports dietary fat and cholesterol in the body.¹ Because chylomicrons are rich in triglycerides, patients with FCS have extremely high levels of triglycerides, reaching 10 to 20 times the normal level. Because people with FCS cannot break down chylomicrons, their blood can appear milky in color (lipemic), and they live at risk of severe recurrent abdominal pain and potentially fatal pancreatitis, long-term complications from pancreatic damage, and symptoms that can interfere with daily living.^{2,3,4}

What Causes FCS?

Lipoprotein lipase (LPL) is an enzyme that works to help break down chylomicrons in the body. In people living with FCS, LPL does not function correctly. This causes a buildup of chylomicrons (particles that carry triglycerides) in the bloodstream.^{5,6,7}

Burden of FCS

People with FCS face significant morbidity and mortality risks including the threat of acute pancreatitis, which can be fatal, and pancreatic damage, which can cause long-term morbidities that can be disabling and affect many aspects of daily life.⁶ In women, factors that increase estrogen levels, including use of oral contraceptives and pregnancy, can spike triglycerides, increasing the risk of pancreatitis, miscarriage and maternal fatality.^{8,9}

A survey of FCS patients showed that:

- 59% reported a history of recurrent abdominal pain without hospitalization; and
- 50% had a history of recurrent pancreatitis (ranging from 2 to 96 episodes).¹⁰

In a separate study of patients experiencing triglyceride-induced pancreatitis,

- 60% required care at an intensive care unit;
- 50% had pancreatic necrosis as identified via contrast CT-scan findings;
- 48% developed persistent organ failure; and
- there was an 8% mortality rate.¹¹

Among all symptoms of FCS, abdominal pain and pancreatitis present the most significant risks to patients. Pancreatitis typically begins with extreme nausea, vomiting, sweats and pain in the upper abdomen that radiates to the back and ribcage.¹² In severe cases, patients describe the pain associated with pancreatitis as excruciating and intolerable – “like a knife repeatedly stabbing me on the side” or “like someone took a power drill to the side of your rib cage.”^{7,13,14,15}

Many people living with FCS report experiencing episodes of fatigue, lack of energy (asthenia), impaired cognition and numbness/tingling.^{13,16,17} Patients report that fatigue and pain caused by FCS can affect their ability to work, while dietary restrictions and fear of attacks of pancreatitis can restrict opportunities to participate in many social activities or travel.⁵

Diagnosis


Receiving a specific diagnosis of FCS is crucial to receiving the right education, medical care, and support from others living with this disease. Because high triglycerides and pancreatitis have many causes, doctors may not recognize cases of FCS. Many patients report that they experienced symptoms including severe abdominal pain and pancreatitis for several months or even years before they received an FCS diagnosis.

Optimal management requires a care team of HCPs, and may include a lipid specialist for triglyceride management, gastroenterologist for support managing abdominal pain and gastrointestinal symptoms, a registered dietitian to help with dietary choices, and a primary care physician.⁸ With a diagnosis, patients with FCS can meet and support each other by connecting through organizations such as the FCS Foundation.

The Continuing Unmet Need in FCS^{18,19,20,21}

There are currently no approved therapies for the treatment of FCS. Available therapies used to reduce triglyceride levels, including niacin and fibrates, work by targeting the LPL pathway. In FCS this pathway does not function properly, making these options ineffective.

Current standard of care in managing FCS often involves severe dietary restrictions to avoid increasing triglyceride levels. Many people living with FCS limit fat intake to only 10-12 grams per day (there are 14 grams of fat in a single tablespoon of olive oil) and still experience episodes of pancreatitis.



Learn More

For more information about FCS diagnosis and management, visit [fcsfocus.com](https://www.fcsfocus.com).

The FCS Foundation is also on the web at [livingwithfcs.org](https://www.livingwithfcs.org), on Facebook at [facebook.com/fightFCS](https://www.facebook.com/fightFCS), and on Twitter at [@livingwithfcs](https://twitter.com/livingwithfcs).

References

- ¹ Brahm AJ, Hegele RA. Chylomicronaemia – current diagnosis and future therapies. *Nat Rev Endocrinol*. 2015;11(6):352-362.
- ² Blom D. Hypertriglyceridaemia: aetiology, complications and management. *JEMDSA*. 2010;15(1):11-17.
- ³ Corfield AP, Cooper MJ, Williamson RC. Acute pancreatitis: a lethal disease of increasing incidence. *Gut*. 1985;26(7):724-729.
- ⁴ Gaudet D, Stroes ES, Methot J, et al. Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. *Hum Gene Ther*. 2016;27(11):916-925.
- ⁵ Brown A, Ross J, Gilstrap A, Hsieh A, Williams K, Gelrud A(2016, September). The burden of illness and psychosocial consequences of living with familial chylomicronemia syndrome (FCS): Patient and caregiver perspectives. Poster session presented at the 2016 Congress of the American Society for Preventative Cardiology, Boca Raton, FL.
- ⁶ Gaudet, Daniel et al. Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologists. *Journal of Clinical Lipidology*, Volume 10 , Issue 3, 680-681.
- ⁷ Chait A, Brunzell JD. Chylomicronemia syndrome. *Adv Intern Med*. 1992;37:249-273.
- ⁸ Gupta N, Ahmed S, Shaffer L, Cavens P, Blankstein J. Severe hypertriglyceridemia induced pancreatitis in pregnancy. *Case Rep Obstet Gynecol*. 2014;2014:485493.
- ⁹ Kayatas SE, Eser M, Cam C, Cogendez E, Guzin K. Acute pancreatitis associated with hypertriglyceridemia: a life-threatening complication. *Arch Gynecol Obstet*. 2010;281(3):427-429.
- ¹⁰ Kawashiri MA, Higashikata T, Mizuno M, et al. Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. *J Clin Endocrinol Metab*. 2005 Dec;90(12):6541-4.
- ¹¹ Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. *Am J Gastroenterol*. 2015;110(10):1497-1503. pancreatitis, retained glucose tolerance, and atherosclerosis. *J Clin Endocrinol Metab*. 2005;90(12):6541-6544.
- ¹² National Organization for Rare Disorders. NORD guides for physicians. The physician's guide to lipoprotein lipase deficiency (LPLD). Available at: http://nordphysicianguides.org/wp-content/uploads/2015/04/NORD_Physician%E2%80%99s-Guide-to-Lipoprotein-Lipase-Deficiency.pdf.
- ¹³ Data on File.
- ¹⁴ Sarr MG, Sakorafas GH. Incapacitating pain of chronic pancreatitis: a surgical perspective of what is known and what needs to be known. *Gastrointest Endosc*. 1999;49(3 Pt 2):S85-S89.
- ¹⁵ CMFB Patient Comment: Pancreatitis Symptoms. Available at: <http://www.medicinenet.com/pancreatitis/patient-comments-36-page3.htm>.
- ¹⁶ Pouwels ED, Blom DJ, Firth JC, Henderson HE, Marais AD. Severe hypertriglyceridemia as a result of familial chylomicronemia: the Cape Town experience. *S Afr Med J*. 2008;98(2):105-108.)
- ¹⁷ Chait A, Robertson T, Brunzell J. Chylomicronemia Syndrome in Diabetes Mellitus. *Diabetes Care*. 1981;4(3):343-8.
- ¹⁸ Williams L, Wilson DP. Editorial commentary: dietary management of familial chylomicronemia syndrome. *J Clin Lipidol*. 2016;10(3):462-465.
- ¹⁹ Brunzell JD. Familial lipoprotein lipase deficiency. *GeneReviews* [Internet]. 2011;
- ²⁰ Sugandhan S, Khandpur S, Sharma VK. Familial chylomicronemia syndrome. *Pediatr Dermatol*. 2007;24(3):323-325.
- ²¹ Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. *J Clin Lipidol*. 2015;9(6 Suppl):S1-122.



A subsidiary of Ionis Pharmaceuticals, Inc.